Eight months in its 2023/24 year, Carl Zeiss Meditec has revised down its revenue and EBIT outlook for the full year due to soft order entry from the equipment business, particularly in North America, and lower consumable orders from its refractive surgery unit in China. Excluding the contribution from DORC, ...
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
Or sign-up for a trial month for just 9,90€. To continue reading this article register now.